Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 2
2003 4
2004 2
2005 4
2006 7
2007 4
2008 2
2009 1
2010 1
2011 3
2012 1
2013 1
2014 4
2015 3
2016 1
2017 1
2019 2
2020 1
2021 2
2022 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group. Doody RS, et al. N Engl J Med. 2014 Jan 23;370(4):311-21. doi: 10.1056/NEJMoa1312889. N Engl J Med. 2014. PMID: 24450890 Free article. Clinical Trial.
Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument.
Amariglio RE, Donohue MC, Marshall GA, Rentz DM, Salmon DP, Ferris SH, Karantzoulis S, Aisen PS, Sperling RA; Alzheimer’s Disease Cooperative Study. Amariglio RE, et al. JAMA Neurol. 2015 Apr;72(4):446-54. doi: 10.1001/jamaneurol.2014.3375. JAMA Neurol. 2015. PMID: 25706191 Free PMC article.
A phase 3 trial of semagacestat for treatment of Alzheimer's disease.
Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study Steering Committee; Siemers E, Sethuraman G, Mohs R; Semagacestat Study Group. Doody RS, et al. N Engl J Med. 2013 Jul 25;369(4):341-50. doi: 10.1056/NEJMoa1210951. N Engl J Med. 2013. PMID: 23883379 Free article. Clinical Trial.
A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients.
Grundman M, Capparelli E, Kim HT, Morris JC, Farlow M, Rubin EH, Heidebrink J, Hake A, Ho G, Schultz AN, Schafer K, Houston W, Thomas R, Thal LJ; Alzheimer's Disease Cooperative Study. Grundman M, et al. Life Sci. 2003 Jun 20;73(5):539-53. doi: 10.1016/s0024-3205(03)00320-5. Life Sci. 2003. PMID: 12770610 Clinical Trial.
Dyadic Enrollment in a Phase 3 Mild Cognitive Impairment Clinical Trial.
Hakhu NR, Gillen DL, Grill JD; Alzheimer’s Disease Cooperative Study. Hakhu NR, et al. Alzheimer Dis Assoc Disord. 2022 Jul-Sep 01;36(3):192-199. doi: 10.1097/WAD.0000000000000506. Epub 2022 Apr 29. Alzheimer Dis Assoc Disord. 2022. PMID: 35482891 Free PMC article.
T2 Protect AD: Achieving a rapid recruitment timeline in a multisite clinical trial for individuals with mild to moderate Alzheimer's disease.
Shadyab AH, LaCroix AZ, Matthews G, Bennett D, Shadyab AA, Tan D, Thomas RG, Mason J, Lopez A, Askew B, Donahue L, Kaplita S, Qureshi IA, Huisa B, Feldman HH; Alzheimer's Disease Cooperative Study T2 Protect AD Study Group. Shadyab AH, et al. Alzheimers Dement (N Y). 2022 Mar 14;8(1):e12265. doi: 10.1002/trc2.12265. eCollection 2022. Alzheimers Dement (N Y). 2022. PMID: 35310528 Free PMC article.
49 results